In particular, sequential administration of pemetrexed followed by ITF2357 was crucial in inducing growth-inhibitory synergism between the two drugs in all NSCLC models tested, at least in part due to ITF2357 ability to downregulate TS expression. The gene discussed is TYMS; the disease is non-small cell lung carcinoma.